Verification of nucleotide sequence reagent identities in original publications in high impact factor cancer research journals
Naunyn-Schmiedeberg's Archives of Pharmacology · 2024
DOI: 10.1007/s00210-023-02846-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2024. Verfasst von Pranujan Pathmendra und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, 2050, Australia. Hauptthemen laut MEDLINE: Journal Impact Factor, Neoplasms, Periodicals as Topic. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Sydney, National Health and Medical Research Council of Australia (NHMRC) Ideas Grant.
Abstract (Originalsprache)
Human gene research studies that describe wrongly identified nucleotide sequence reagents have been mostly identified in journals of low to moderate impact factor, where unreliable findings could be considered to have limited influence on future research. This study examined whether papers describing wrongly identified nucleotide sequences are also published in high-impact-factor cancer research journals. We manually verified nucleotide sequence identities in original Molecular Cancer articles published in 2014, 2016, 2018, and 2020, including nucleotide sequence reagents that were claimed to target circRNAs. Using keywords identified in some 2018 and 2020 Molecular Cancer papers, we also verified nucleotide sequence identities in 2020 Oncogene papers that studied miRNA(s) and/or circRNA(s). Overall, 3.8% (251/6647) and 4.0% (47/1165) nucleotide sequences that were verified in Molecular Cancer and Oncogene papers, respectively, were found to be wrongly identified. Wrongly identified nucleotide sequences were distributed across 18% (91/500) original Molecular Cancer papers, including 38% (31/82) Molecular Cancer papers from 2020, and 40% (21/52) selected Oncogene papers from 2020. Original papers with wrongly identified nucleotide sequences were therefore unexpectedly frequent in two high-impact-factor cancer research journals, highlighting the risks of employing journal impact factors or citations as proxies for research quality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, 2050, Australia.
- Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028, Lisbon, Portugal.
- School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, 2050, Australia. jennifer.byrne@health.nsw.gov.au.
- NSW Health Statewide Biobank, NSW Health Pathology, Camperdown, NSW, 2050, Australia. jennifer.byrne@health.nsw.gov.au.
Förderung
- University of Sydney
- National Health and Medical Research Council of Australia (NHMRC) Ideas Grant
Zitieren
APA
Pathmendra, P., Park, Y., Enguita, F. J., & Byrne, J. A. (2024). Verification of nucleotide sequence reagent identities in original publications in high impact factor cancer research journals. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-023-02846-2
Vancouver
Pathmendra P, Park Y, Enguita FJ, Byrne JA. Verification of nucleotide sequence reagent identities in original publications in high impact factor cancer research journals. Naunyn-Schmiedeberg's Archives of Pharmacology. 2024. doi:10.1007/s00210-023-02846-2
BibTeX
@article{Pathmendra2024,
author = {Pathmendra, Pranujan and Park, Yasunori and Enguita, Francisco J and Byrne, Jennifer A},
title = {Verification of nucleotide sequence reagent identities in original publications in high impact factor cancer research journals},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2024},
doi = {10.1007/s00210-023-02846-2}
}
EUVIMED